Cholinergic stimulation with pyridostigmine reduces ventricular arrhythmia and enhances heart rate variability in heart failure

American Heart Journal

Volumn 146, Issue 3, 2003, Pages 494-500

  Behling, Alice ^b   Moraes, Ruy S ^b   Rohde, Luis E ^b   Ferlin, Elton L ^b   Nóbrega, Antonio C L ^b   Ribeiro, Jorge P ^a  

^a HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; PYRIDOSTIGMINE;

ADULT; AGED; ARTICLE; CHOLINERGIC STIMULATION; CHOLINESTERASE INHIBITION; CLINICAL ARTICLE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; ELECTROCARDIOGRAM; FEMALE; HEART FAILURE; HEART RATE VARIABILITY; HEART VENTRICLE ARRHYTHMIA; HEART VENTRICLE EXTRASYSTOLE; HUMAN; LONG TERM CARE; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RR INTERVAL; SINUS RHYTHM;

EID: 0041526310     PISSN: 00028703     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-8703(03)00319-3     Document Type: Article

References (34)

1. Merit-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: metoprolol CR/XL randomized intervention trial in congestive heart failure (MERIT-HF). Lancet 1999;353:2001-7.
2. Porter TR, Eckberg DL, Fritsch JM, et al. Autonomic pathophysiology in heart failure patients. J Clin Invest 1990;85:1362-71.
3. Nolan J, Batin PD, Andrews R, et al. Prospective study of heart rate variability and mortality in chronic heart failure: results of the United Kingdom heart failure evaluation and assessment of risk trial (UK-Heart). Circulation 1998;98:1510-6.
4. Bonaduce D, Petretta M, Marciano F, et al. Independent and incremental prognostic value of heart rate variability in patients with chronic heart failure. Am Heart J 1999;138:273-84.
5. La Rovere MT, Pinna GD, Hohnloser SH, et al. Baroreflex sensitivity and heart rate variability in the identification of patients at risk for life-threatening arrhythmias: implications for clinical trials. Circulation 2001;103:2072-7.
6. Grimm W, Glaveris C, Hoffmann J, et al. Arrhythmia risk stratification in idiopathic dilated cardiomyopathy based on echocardiography and 12-lead, signal-averaged, and 24-hour Holter electrocardiography. Am Heart J 2000;140:43-51.
7. Kent KM, Smith ER, Redwood DR, et al. Electrical stability of acutely ischemic myocardium: influences of heart rate and vagal stimulation. Circulation 1973;47:291-8.
8. De Ferrari GM, Salvati P, Grossoni M, et al. Pharmacologic modulation of the autonomic nervous system in the prevention of sudden cardiac death: a study with propranolol, methacoline and oxotremorine in conscious dogs with a healed myocardial infarction. J Am Coll Cardiol 1993;22:283-90.
9. Waxman MB, Wald RW. Termination of ventricular tachycardia by increase in cardiac vagal drive. Circulation 1977;56:385-91.
10. Nóbrega ACL, Castro RRT. Parasympathetic dysfunction as a risk factor in myocardial infarction: what is the treatment? Am Heart J 2000;140:e23.
11. Nóbrega ACL, Reis AF, Moraes RS, et al. Enhancement of heart rate variability by cholinergic stimulation with pyridostigmine in healthy subjects. Clin Auton Research 2001;11:11-7.
12. Polanczyk CA, Rohde LEP, Moraes RS, et al. Sympathetic nervous system representation in time and frequency domain indices of heart rate variability. Eur J Appl Physiol 1998;79:69-73.
13. Task force of the European Society of Cordiology and the North American Society of Pacing and Eletrophysiology. Heart rate variability: standards of measurement, physiological interpretation and clinical use. Circulation 1996;93:1046-65.
14. Sahn DJ, DeMaria A, Kisslo A, et al. Recommendations regarding quantittation in M-mode echocardiography: results of a survey of echocardiography measurements. Circulation 1978;58:1072-86.
15. Azevedo MJ, Pinotti AF, Stumpf S, et al. Preserved left ventricular systolic and diastolic function in normoalbuminuric insulin-dependent diabetic patients with glomerular hyperfiltration. Diabetes Res Clin Practice 1994;25:103-10.
16. Rohde LEP, Polanczyk CA, Moraes RS, et al. Effect of partial arrhythmia supression with amiodarone on heart rate variability of patients with congestive heart failure. Am Heart J 1998;136:31-6.
17. Taylor P. Anticholinesterase agents. In: Hardman JG, Limbird LE, editors. Goodman and Gilman's pharmacological basis of therapeutics. New York: McGraw-Hill; 2001. p. 175-98.
18. Stein RD, Backman SB, Collier B, et al. Bradycardia produced by pyridostigmine and physostigmine. Can J Anaesth 1997;44:1286-92.
19. Nóbrega ACL, Carvalho ACG, Bastos BG. Resting and reflex heart rate responses during cholinergic stimulation with pyridostigmine in humans. Brazilian J Med Biol Res 1996;29:1461-5.
20. Pontes PV, Bastos BG, Romea Filho RJ, et al. Cholinergic stimulation with pyridostigmine: hemodynamic and echocardiographic analysis in healthy subjects. Arq Bras Cardiol 1999;72:297-306.
21. Nóbrega ACL, Carvalho ACG, Santos KB, et al. Cholinergic stimulation with pyridostigmine blunts the cardiac responses to mental stress. Clin Auton Res 1999;9:1-6.
22. Serra SM, Costa RV, Bastos BG, et al. Cardiopulmonary exercise testing during cholinergic stimulation with single dose of pyridostigmine in healthy subjects. Arq Bras Cardiol 2001;76:279-84.
23. Castro RR, Serra SM, Nóbrega AC. Reduction of QTc interval dispersion: potential mechanism of cardioc protection of pyridostigmine bromide. Arq Bras Cardiol 2000;75:205-13.
24. Grabe-Guimarães A, Alves LM, Tibiriçá E, et al. Pyridostigmine blunts the increases in myocardial oxygen demand elicited by the stimulation of the central nervous system in anesthetized rats. Clin Auton Res 1999;9:83-9.
25. Michelson EL, Morganroth J. Spontaneous variability of complex ventricular arrhythmias detected by long-term electrocardiographic recording. Circulation 1980;61:690-5.
26. Pratt CM, Théroux P, Slymen D, et al. Spontaneous variability of ventricular arrhythmias in patients at increased risk for sudden death after acute myocardial infarction. Am J Cardiol 1987;59:278-83.
27. Azevedo ER, Parker JD. Parasympathetic control of cardiac sympathetic activity: normal ventricular function versus congestive heart failure. Circulation 1999;100:274-9.
28. Warner MR, Zipes DP. Vagal control of myocardial refractoriness. In: Levy MN, Schwartz PJ, editors. Vagal control of the heart: experimental basis and clinical implications. Armonk (NY): Futura Publishing; 1994. p. 261-75.
29. Mitrani RD, Kloosterman EM, Huikuri H, et al. Muscarinic receptor stimulation with edrophonium hydrochloride does not elevate ventricular fibrillation threshold in humans. J Cardiovasc Electrophysiol 1999;10:809-16.
30. La Rovere MT, Mortara A, Pantaleo P, et al. Scopolamine improves autonomic balance in advanced congestive heart failure. Circulation 1994;90:838-43.
31. Hull SH Jr, Vanoli E, Adamsom PB, et al. Do increases in markers of vagal activity imply protection from sudden death? The case of scopolamine. Circulation 1995;91:2516-9.
32. Katona PG, Poitras JW, Barnett GO, et al. Cardiac vagal efferent activity and heart period in the carotid sinus reflex. Am J Physiol 1970;218:1030-7.
33. Goldberger JJ, Challapalli S, Tung R, et al. Relationship of heart rate variability to parasympathetic effect. Circulation 2001;103:1977-83.
34. Levy MN, Pappano AJ. Vagal control of myocardial contractility. In: Levy MN, Schwartz PJ, editors. Vagal control of the heart: experimental basis and clinical implications. Armonk (NY): Futura Publishing; 1994. p. 241-59.